Biblio

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

S

De Pieri A, Rana S, Korntner S, Zeugolis DI. Seaweed polysaccharides as macromolecular crowding agents. Int J Biol Macromol. 2020.

Liu C, Mentzelopoulou A, Papagavriil F, Ramachandran P, Perraki A, Claus L, Barg S, Dörmann P, Jaillais Y, Johnen P, et al. SEC14-like condensate phase transitions at plasma membranes regulate root growth in Arabidopsis. PLoS Biol. 2023;21(9):e3002305.

Zheng Y, Mennella V, Marks S, Wildonger J, Elnagdi E, Agard D, Megraw TL. The Seckel syndrome and centrosomal protein Ninein localizes asymmetrically to stem cell centrosomes, but is not required for normal development, behavior, or DNA damage response in Drosophila. Mol Biol Cell. 2016.

Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.

Kudo K, Muramatsu H, Yoshida N, Kobayashi R, Yabe H, Tabuchi K, Kato K, Koh K, Takahashi Y, Hashii Y, et al. Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia. Bone Marrow Transplant. 2015.

Laberko A, Sultanova E, Idarmacheva A, Skvortsova Y, Shelikhova L, Nechesnyuk A, Kobyzeva D, Shcherbina A, Maschan M, Maschan A, et al. Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity. Bone Marrow Transplant. 2022.

Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019.

Christopeit M, Kuss O, Finke J, Bacher U, Beelen DWilhelm, Bornhäuser M, Schwerdtfeger R, Bethge WAndreas, Basara N, Gramatzki M, et al. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. J Clin Oncol. 2013.

van Rhijn-Brouwer FCC, Spierings J, van Rhenen A, Kuball J, van Laar JM. Second autologous haematopoietic stem cell transplantation in systemic sclerosis-a case report. Rheumatology (Oxford). 2019.

Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, et al. Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2019.

Yeh S-P, Lin C-C, Lin C-H, Lo W-C, Chen T-T, Lo W-J, Lin C-L, Chiu C-F. Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2015.

Velázquez GFilippini, Labopin M, Tischer J, Raiola AMaria, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois C-E, Kröger N, et al. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.

Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, Nagler A, Shimoni A. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/ myelodysplastic syndromes after a first transplantation. Haematologica. 2022.

Mao J-Q, Song H, Yang S-L, Zhao F-Y, Shen D-Y, Tang Y-M. [Second HLA-identical related hematopoietic stem cells transplantation for juvenile myelomonocytic leukemia: one case report]. Zhongguo Dang Dai Er Ke Za Zhi. 2013;15(7):591-3.

Czyż A, Lojko-Dankowska A, Matuszak M, Dytfeld D, Kaźmierczak M, Komarnicki M. Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis. Contemp Oncol (Pozn). 2013;17(2):200-204.

Applebaum MA, Henderson TO, Lee SMee, Pinto N, Volchenboum SL, Cohn SL. Second malignancies in patients with neuroblastoma: The effects of risk-based therapy. Pediatr Blood Cancer. 2014.

Zhan Z, Guo W, Wan X, Bai O. Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors. Ann Hematol. 2023.

Trab T, Baech J, Jakobsen LHjort, Husby S, Severinsen MTang, Eloranta S, Gørløv JS, Jørgensen JM, Gudbrandsdottir S, Larsen TStauffer, et al. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol. 2023.

Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MChiara, Caramella M, Rumi E, Carraro MCristina, Polverelli N, et al. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Adv. 2019;3(21):3196-3200.

Fürstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, Jacobasch L, Dörfel S, Aldaoud A, von Tresckow J, et al. Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am J Hematol. 2021.

Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.

Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J, Kanz L, Blaise D, et al. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant. 2015.

Lupo-Stanghellini MTeresa, Piemontese S, Assanelli A, Serpenti F, Mastaglio S, Clerici D, Giglio F, Greco R, Lorentino F, Pavesi F, et al. Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up. Hemasphere. 2021;5(11):e654.

Faust C, Dietrich-Ntoukas T, Steven P. [Second Survey on Patient-centred Care of Ocular Graft-versus-Host Disease in Germany]. Klin Monbl Augenheilkd. 2019.

Han T, Sun Y, Liu Y, Yan C, Wang Y, Xu L, Liu K, Huang X, Zhang X. Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion. Front Med. 2021.

Pages